Titan is reporting further evidence that Zomaril (iloperidone), their SDA for Schizophrenia, is a significant improvement versus current antipsychotic regimens. While we await publication of today's data, this SDA is now strongly suggesting a win/win scenario: a reduction in both positive and negative symtomology together with substantially fewer extrapyramidal, cardiac, weight-related etc. contaminating factors. While win/win may be the case, there remain few patients treated thus far with iloperidone, few published studies on the drug, and few direct comparisons to other atypical antopsychotics (clozapine, iloperidone, quetiapine, olanzapine, risperidone, ziprasidone etc.).
Larger and more inclusive trials will be required to fully support any excitement today's news engenders. |
